Wnt6 contributes tumorigenesis and development of colon cancer via its effects on cell proliferation, apoptosis, cell‑cycle and migration

Zheng ,Xiao‑Li; Yu,Hong‑Gang

doi:10.3892/ol.2018.8729

Wnt6 contributes tumorigenesis and development of colon cancer via its effects on cell proliferation, apoptosis, cell‑cycle and migration

Authors:
- Xiao‑Li Zheng
- Hong‑Gang Yu
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: May 16, 2018 https://doi.org/10.3892/ol.2018.8729
Pages: 1163-1172

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wnt proteins have been reported to contribute to the progression of various types of cancer. Wnt6 is a member of the Wnt family and may promote tumorigenesis in gastrointestinal cancer and cervical cancer. In the present study, the expression of Wnt6 in human colon cancer cell lines was evaluated, in order to investigate the role of Wnt6 in the development of colon cancer. Additionally, the effects of Wnt6 upregulation or downregulation on proliferation, apoptosis, cell cycle and cell migration of colon cancer cells have been investigated. Furthermore, western blot analysis was employed to evaluate the expression of Wnt6, B‑cell lymphoma 2‑associated X protein (Bax), caspase‑3 and matrix metalloproteinase (MMP)2. The results of the present study demonstrated that the expression of Wnt6 was increased in HCT116 and SW480 cells compared with the remaining colon cancer cell lines. Furthermore, overexpression Wnt6 resulting from transfection of pGPU6/GFP/Neo‑Wnt6‑Homo‑1 plasmid promoted the proliferation, cell cycle and migration of HCT116 and SW480 cells, but inhibited cell apoptosis in vitro. The expression of caspase‑3 and MMP2 was increased, whereas the expression of Bax was decreased in response to upregulation of Wnt6. These results suggested that Wnt6 may serve a vital function in the development of colon cancer.

View Figures

View References

1	Ahmed S, Johnson K, Ahmed O and Iqbal N: Advances in the management of colorectal cancer: From biology to treatment. Int J Colore Dis. 29:1031–1042. 2014. View Article : Google Scholar
2	László L: Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol. 54:383–394. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sung JJ, Lau JY, Goh KL and Leung WK: Asia Pacific Working Group on Colorectal Cancer: Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
4	Hu T, Li Z, Gao CY and Cho CH: Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
5	Shi W, Ye Z, Zhuang L, Li Y, Shuai W, Zuo Z, Mao X, Liu R, Wu J, Chen S and Huang W: Olfactomedin 1 negatively regulates NF-kB signalling and suppresses the growth and metastasis of colorectal cancer cells. J Pathol. 240:352–365. 2016. View Article : Google Scholar : PubMed/NCBI
6	Yan H, Hu K, Wu W, Li Y, Tian H, Chu Z, Koeffler HP and Yin D: Low expression of DYRK2 (Dual specificity tyrosine phosphorylation regulated kinase 2) correlates with poor prognosis in colorectal cancer. PLoS One. 11:e01599542016. View Article : Google Scholar : PubMed/NCBI
7	Zhang Y, Lin C, Liao G, Liu S, Ding J, Tang F, Wang Z, Liang X, Li B, Wei Y, et al: MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. Oncotarget. 6:32586–32601. 2015.PubMed/NCBI
8	Zhou FQ, Qi YM, Xu H, Wang QY, Gao XS and Guo HG: Expression of EpCAM and Wnt/β-catenin in human colon cancer. Genet Mol Res. 14:4485–4494. 2015. View Article : Google Scholar : PubMed/NCBI
9	Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR and Limburg PJ: Associations between cigarette smoking status and colon cancer prognosis among participants in North central cancer treatment group phase III trial N0147. J Clin Oncol. 31:2016–2023. 2013. View Article : Google Scholar : PubMed/NCBI
10	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
11	Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, Tang N, Haydon RC, Luu HH and He TC: Wnt signaling and human diseases: What are the therapeutic implications? Lab Invest. 87:97–103. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bienz M and Clevers H: Linking colorectal cancer to Wnt signaling. Cell. 103:311–320. 2000. View Article : Google Scholar : PubMed/NCBI
13	Basu S, Haase G and Ben-Ze'ev A: Wnt signaling in cancer stem cells and colon cancer metastasis. F1000Res. 5:pii: F1000 Faculty Rev. –699. 2016. View Article : Google Scholar
14	Kikuchi A: Canonical Wnt signaling pathway and cellular responses. Clin Calcium. 23:799–807. 2013.(In Japanese). PubMed/NCBI
15	Kirikoshi H, Sekihara H and Katoh M: WNT10A and WNT6, clustered in human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed in SW480 cells. Biochem Biophys Res Commun. 283:798–805. 2001. View Article : Google Scholar : PubMed/NCBI
16	Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Ströbel P, Langer R, Keller G, Röcken C, et al: WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene. 32:375–387. 2013. View Article : Google Scholar : PubMed/NCBI
17	Katoh M: WNT and FGF gene clusters (review). Int J Oncol. 21:1269–1273. 2002.PubMed/NCBI
18	Lavery DL, Davenport IR, Turnbull YD, Wheeler GN and Hoppler S: Wnt6 expression in epidermis and epithelial tissues during Xenopus organogenesis. Dev Dyn. 237:768–779. 2008. View Article : Google Scholar : PubMed/NCBI
19	Galbraith RL, Poole EM, Duggan D, Muehling J, Hsu L, Makar K, Xiao L, Potter JD and Ulrich CM: Polymorphisms in WNT6 and WNT10A and colorectal adenoma risk. Nutr Cancer. 63:558–564. 2011. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Na YJ, Jeon YJ, Suh JH, Kang JS, Yang KH and Kim HM: Suppression of IL-8 gene expression by radicicol is mediated through the inhibition of ERK1/2 and p38 signaling and negative regulation of NF-kappaB and AP-1. Int Immunopharmacol. 1:1877–1887. 2001. View Article : Google Scholar : PubMed/NCBI
22	Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T, Liu Y, Li X, Xiang R and Li N: SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/β-catenin signal network. Cancer Lett. 336:379–389. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003.PubMed/NCBI
24	Kirikoshi H, Sekihara H and Katoh M: Up-regulation of WNT10A by tumor necrosis factor alpha and Helicobacter pylori in gastric cancer. Int J Oncol. 19:533–536. 2001.PubMed/NCBI
25	Mukherjee N, Bhattacharya N, Alam N, Roy A, Roychoudhury S and Panda CK: Subtype-specific alterations of the Wnt signaling pathway in breast cancer: Clinical and prognostic significance. Cancer Sci. 103:210–220. 2012. View Article : Google Scholar : PubMed/NCBI
26	Guillen-Ahlers H: Wnt signaling in renal cancer. Curr Drug Targets. 9:591–600. 2008. View Article : Google Scholar : PubMed/NCBI
27	Chen GAJ, Wang M, Farley S, Lee LY, Lee LC and Sawicki MP: Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol Cancer Res. 6:1894–1907. 2008.PubMed/NCBI
28	Robinson DR, Zylstra CR and Williams BO: Wnt signaling and prostate cancer. Curr Drug Targets. 9:571–580. 2008. View Article : Google Scholar : PubMed/NCBI
29	Larue L and Delmas V: The WNT/Beta-catenin pathway in melanoma. Front Biosci. 11:733–742. 2006. View Article : Google Scholar : PubMed/NCBI
30	Modder UI, Oursler MJ, Khosla S and Monroe DG: Wnt10b activates the Wnt, notch, and NFkB pathways in U2OS osteosarcoma cells. J Cell Biochem. 112:1392–1402. 2011. View Article : Google Scholar : PubMed/NCBI
31	Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Ströbel P, Langer R, Keller G, Röcken C, et al: WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene. 32:375–387. 2013. View Article : Google Scholar : PubMed/NCBI
32	Wieczorek M, Paczkowska A, Guzenda P, Majorek M, Bednarek AK and Lamparska-Przybysz M: Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells. Cancer Biol Ther. 7:268–274. 2008. View Article : Google Scholar : PubMed/NCBI
33	Jung YS, Jun S, Lee SH, Sharma A and Park JI: Wnt2 complements Wnt/β-catenin signaling in colorectal cancer. Oncotarget. 6:37257–37268. 2015. View Article : Google Scholar : PubMed/NCBI
34	Huang C, Ma R, Xu Y, Li N, Li Z, Yue J, Li H, Guo Y and Qi D: Wnt2 promotes non-small cell lung cancer progression by activating WNT/β-catenin pathway. Am J Cancer Res. 5:1032–1046. 2015.PubMed/NCBI
35	Chen H, Wang Y and Xue F: Expression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/β-catenin pathway. Oncol Rep. 29:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
36	Cao LH, Li HT, Lin WQ, Tan HY, Xie L, Zhong ZJ and Zhou JH: Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 6:187062016. View Article : Google Scholar : PubMed/NCBI
37	Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
38	Sugimoto C, Fujieda S, Seki M, Sunaga H, Fan GK, Tsuzuki H, Borner C, Saito H and Matsukawa S: Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int J Cancer. 82:860–867. 1999. View Article : Google Scholar : PubMed/NCBI
39	Lee EH, Chari R, Lam A, Ng RT, Yee J, English J, Evans KG, Macaulay C, Lam S and Lam WL: Disruption of the Non-canonical WNT pathway in lung squamous cell carcinoma. Clin Med Oncol. 2:169–179. 2008.
40	Ramel MC and Lekven AC: Repression of the vertebrate organizer by Wnt8 is mediated by Vent and Vox. Development. 131:3991–4000. 2004. View Article : Google Scholar : PubMed/NCBI